PHAR

Pharming Group N.V. ADR

Feb 05 • 04:00PM ET

16.04

-0.84 -4.98 %

Healthcare • Biotechnology • Netherlands • NASD

Feb 04, 4:30 AMPharming Group issues 2026 revenue guidance of $405–$425 million above consensus and reports preliminary 2025 revenue of about $376 million at its Investor Day, while flagging FDA questions on Joenja’s pediatric APDS label expansion and outlining increased R&D spend for late-stage pipeline.

Peers: VRTX AMGN BBIO BIIB GILD REGN NBIX INCY RARE QURE

Scroll to Statements

Index	-	P/E	1113.89	EPS (ttm)	0.01	Insider Own	-	Shs Outstand	68.51M	Perf Week	-22.47%
Market Cap	1.13B	Forward P/E	91.14	EPS next Y	0.18	Insider Trans	-	Shs Float	-	Perf Month	-4.86%
Enterprise Value	1.09B	PEG	-	EPS next Q	0.01	Inst Own	1.30%	Short Float	-	Perf Quarter	21.87%
Income	1.07M	P/S	3.10	EPS this Y	119.22%	Inst Trans	93.62%	Short Ratio	0.61	Perf Half Y	30.51%
Sales	362.44M	P/B	4.15	EPS next Y	472.36%	ROA	0.24%	Short Interest	0.02M	Perf YTD	-9.22%
Book/sh	3.86	P/C	6.74	EPS next 5Y	-	ROE	0.44%	52W High	21.34 -24.84%	Perf Year	76.46%
Cash/sh	2.38	P/FCF	22.96	EPS past 3/5Y	- -	ROIC	0.28%	52W Low	7.50 113.82%	Perf 3Y	44.88%
Dividend Est.	-	EV/EBITDA	24.38	Sales past 3/5Y	14.32% 9.42%	Gross Margin	89.16%	Volatility	5.44% 3.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	3.00	EPS Y/Y TTM	105.57%	Oper. Margin	9.38%	ATR (14)	1.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.39	Sales Y/Y TTM	26.54%	Profit Margin	0.29%	RSI (14)	37.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.16	EPS Q/Q	817.11%	SMA20	-14.38%	Beta	0.03	Target Price	30.57
Payout	-	Debt/Eq	0.49	Sales Q/Q	29.05%	SMA50	-9.51%	Rel Volume	2.32	Prev Close	16.88
Employees	-	LT Debt/Eq	0.46	Earnings	Nov 06 BMO	SMA200	17.95%	Avg Volume	28.55K	Price	16.04
IPO	Dec 23, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	2122.22% -0.94%	Trades		Volume	66,086	Change	-4.98%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-24	Initiated	Jefferies	Buy	$14

Feb-04-26 04:18AM	Pharming Group Investor Day: 2026 revenue outlook tops Street as Joenja growth, readouts loom (MarketBeat)
Feb-02-26 04:24PM	Why Pharming, A Top 3% Biotech Stock, Just Took A Double-Digit Beating (Investor's Business Daily) -17.07%
09:04AM	FDA Strikes Off European Biotech Pharming's Immune Deficiency Drug For Expanded Use In Pediatric Patients (Benzinga)
Dec-22-25 10:15AM	Best Momentum Stocks to Buy for Dec. 22 (Zacks) +6.56%
Nov-26-25 09:55AM	Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade (Zacks)
09:15AM	Loading…
Nov-20-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? (Zacks)
Nov-10-25 12:20PM	Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? (Zacks) +13.74%
09:55AM	Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect? (Zacks)
Nov-05-25 07:43AM	What To Expect From Pharming Group (XAMS:PHARM) Q3 2025 Earnings (GuruFocus.com)
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks) -6.82%
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
Sep-22-25 11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-15-25 09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks) -5.38%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks) +9.55%
11:12AM	Loading…
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-04-25 11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks) -5.94%
Aug-29-25 10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks) -6.16%
Aug-22-25 09:55AM	Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High? (Zacks) +8.21%
Aug-06-25 09:55AM	Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet (Zacks)
Aug-04-25 02:00AM	Pharming Group to participate in August investor conference (GlobeNewswire) +11.77%
Aug-01-25 05:25AM	New Strong Buy Stocks for August 1st (Zacks)
Jul-31-25 01:00AM	Pharming Group reports second quarter and first half 2025 financial results and provides business update (GlobeNewswire) +10.11%
Jul-25-25 10:00AM	Best Momentum Stocks to Buy for July 25th (Zacks)
07:12AM	New Strong Buy Stocks for July 25th (Zacks)
Jul-17-25 10:00AM	Best Momentum Stocks to Buy for July 17th (Zacks)
05:38AM	New Strong Buy Stocks for July 17th (Zacks)
02:00AM	Loading…
02:00AM	Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31 (GlobeNewswire)
Jun-24-25 01:00AM	Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis (GlobeNewswire) +8.58%
Jun-11-25 11:15AM	Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders (GlobeNewswire)
May-28-25 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire) -7.22%
May-08-25 01:00AM	Pharming Group reports first quarter 2025 financial results and provides business update (GlobeNewswire) +11.22%
Apr-30-25 11:45AM	Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director (GlobeNewswire)
Apr-25-25 09:00AM	Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) (GlobeNewswire)
08:09AM	SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-25 10:55AM	Pharming announces positive recommendation from NICE for Joenja (TipRanks)
02:00AM	Pharming Group to report first quarter 2025 financial results on May 8 (GlobeNewswire)
Apr-23-25 03:30AM	Pharming receives positive recommendation from NICE for Joenja (leniolisib) as a treatment for APDS (GlobeNewswire)
Apr-03-25 01:00AM	Pharming Group announces the filing of its 2024 Annual Report and Form 20-F (GlobeNewswire) -8.11%
Apr-01-25 08:45AM	Pharming Group: Small Dutch Company With Strong Revenues (Seeking Alpha)
Mar-28-25 03:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-20-25 02:00AM	Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation (GlobeNewswire)
Mar-13-25 02:00AM	Pharming Group reports fourth quarter and full year 2024 financial results and provides business update (GlobeNewswire) +12.92%
Mar-04-25 09:15AM	Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders (GlobeNewswire)
Feb-28-25 02:00AM	Pharming Group to participate in March investor conference (GlobeNewswire)
Feb-27-25 02:00AM	Pharming Group to report fourth quarter and full year 2024 financial results on March 13 (GlobeNewswire) -6.62%
Feb-20-25 04:00PM	Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent (GlobeNewswire) +5.05%
Feb-10-25 02:00AM	Pharming Group to participate in February investor conference (GlobeNewswire)
Feb-07-25 04:00PM	Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period (GlobeNewswire)
Jan-21-25 12:00PM	Pharming Group to convene Extraordinary General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer (GlobeNewswire)
Dec-15-24 01:45PM	Pharming announces public cash offer to the shareholders of Abliva AB (GlobeNewswire)
Dec-11-24 01:00AM	Pharming announces positive topline data in pediatric clinical trial of leniolisib (GlobeNewswire) +6.07%
Nov-05-24 02:00AM	Pharming Group to participate in November investor conference (GlobeNewswire)
Oct-24-24 01:00AM	Pharming Group reports third quarter 2024 financial results and provides business update (GlobeNewswire) -7.37%
Oct-10-24 02:00AM	Pharming Group to report third quarter 2024 financial results on October 24 (GlobeNewswire)
01:00AM	Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation (GlobeNewswire)
Sep-26-24 01:00AM	Pharming announces marketing authorization in the U.K. for Joenja (leniolisib) (GlobeNewswire)
Sep-04-24 01:00AM	Pharming Group to participate in September investor conferences (GlobeNewswire)
Aug-01-24 01:00AM	Pharming Group reports second quarter and first half 2024 financial results and provides business update (GlobeNewswire) -8.40%
Jul-18-24 02:00AM	Pharming Group to report second quarter and first half 2024 financial results on August 1 (GlobeNewswire)
Jun-03-24 02:00AM	Pharming Group to participate in June investor conferences (GlobeNewswire)
May-30-24 04:44PM	Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union (GlobeNewswire)
May-21-24 11:30AM	Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
May-20-24 02:00AM	Pharming Group to participate in May investor conference (GlobeNewswire)
May-15-24 01:00AM	Pharming Group announces the early redemption of the remaining outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
May-08-24 06:52AM	PHAR Stock Earnings: Pharming Reported Results for Q1 2024 (InvestorPlace)
06:16AM	Pharming Group uproots angioedema gene therapy collab with Orchard (FierceBiotech.com)
01:00AM	Pharming Group reports first quarter 2024 financial results and provides business update (GlobeNewswire)
May-02-24 06:00AM	Genomenon Partners with Pharming to Advance APDS Diagnosis (PR Newswire)
Apr-24-24 02:00AM	Pharming Group to report first quarter 2024 financial results on May 8 (GlobeNewswire)
01:00AM	Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD ) 2024 Rare Impact Awards (GlobeNewswire)
Apr-22-24 05:29AM	Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains? (Zacks)
Apr-19-24 12:43PM	Pharming Group announces the repurchase of outstanding 125 million convertible bonds due 2025 (GlobeNewswire) +7.18%
Apr-18-24 09:04AM	Pharming Group announces the placement of 100 million convertible bonds due 2029 (GlobeNewswire) -8.26%
02:00AM	Pharming Group announces the launch of an offering of approximately 100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding 125 million convertible bonds due 2025 (GlobeNewswire)
Apr-08-24 01:00AM	Pharming announces completion of enrollment in pediatric clinical trial of leniolisib (GlobeNewswire)
Apr-04-24 02:30AM	Pharming Group announces the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
01:00AM	Pharming Group announces the filing of its 2023 Annual Report and Form 20-F (GlobeNewswire)
Apr-03-24 02:00AM	Pharming Group to participate in April investor conferences (GlobeNewswire)
Mar-14-24 02:00AM	Pharming Group reports fourth quarter and full year 2023 financial results (GlobeNewswire)
Feb-29-24 02:00AM	Pharming Group to report fourth quarter and full year 2023 financial results on March 14 (GlobeNewswire)
Feb-08-24 02:00AM	Pharming Group to participate in February investor conferences (GlobeNewswire) -7.19%
Jan-08-24 01:29AM	Pharming Group Projects 2023 Total Revenues To Rise 19% (RTT News)
01:00AM	Pharming Group announces updated full year 2023 guidance and Joenja U.S. launch update (GlobeNewswire)
Dec-13-23 01:00AM	Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) (GlobeNewswire)
Nov-21-23 01:00AM	Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib (GlobeNewswire)
Nov-10-23 08:51AM	Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval (GlobeNewswire) -10.78%
Nov-07-23 02:00AM	Pharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting (GlobeNewswire)
Nov-01-23 03:00AM	Pharming Group to participate in November investor conferences (GlobeNewswire)
Oct-26-23 01:00AM	Pharming Group reports third quarter 2023 financial results (GlobeNewswire) +5.00%
Oct-12-23 02:00AM	Pharming Group to report third quarter 2023 financial results on October 26 (GlobeNewswire)
Sep-25-23 10:00AM	Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders (GlobeNewswire)
Aug-24-23 02:00AM	Pharming Group to participate in September investor conferences (PR Newswire)
Aug-14-23 01:00AM	Pharming Group to convene Extraordinary General Meeting of Shareholders (PR Newswire)
Aug-09-23 01:00AM	Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan (PR Newswire)
Aug-03-23 01:00AM	Pharming Group reports second quarter and first half 2023 financial results (PR Newswire)

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST, Joenja, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHAR

Pharming Group N.V. ADR

Upgrade your FINVIZ experience